Study of YM155 plus docetaxel as the first treatment option for patients with Her2 negative metastatic breast cancer
- Conditions
- Adenocarcinoma of the breast that is HER2 negative.MedDRA version: 14.0 Level: PT Classification code 10006187 Term: Breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2009-012439-14-GB
- Lead Sponsor
- Astellas Pharma Global Development, Inc. (APGD)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 100
A subject is eligible for the study if all of the following apply:
1. The subject prior to any study-related procedures (including withdrawal of prohibited medicines, if applicable) has provided Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)- approved written Informed Consent and privacy language as per national regulations (e.g., HIPAA Authorization for US sites).
2. The subject is male or female and aged 18 years or older at the Baseline Visit with
metastatic breast cancer.
3. The subject has histologically- or cytologically-proven adenocarcinoma of the
breast that is HER2 negative defined as one of the following:
o Negative fluorescence in-situ hybridization (FISH).
o 0 or 1+ immunohistochemistry (IHC).
o IHC 2+ with negative FISH.
Subjects with hormone receptor positive or negative status are eligible. Additionally,
subjects with triple negative status (meaning estrogen receptor negative, rogesterone receptor negative and HER2 negative) are eligible.
4. The subject has received no prior chemotherapy regimen for metastatic breast cancer.
o Prior treatment with a cytotoxic therapy (other than docetaxel) is allowed if
administered in the neoadjuvant or adjuvant setting >3 weeks prior to the Baseline
Visit, with all side effects of using prior cytotoxic therapy resolved or back to
baseline (with the exception of weight loss or gain, anorexia, alopecia or fatigue).
o Prior treatment with docetaxel is allowed if administered in the neoadjuvant or
adjuvant setting, and the subject has no recurrent disease within 12 months after
completing treatment, with all side effects of prior docetaxel use resolved or back to
baseline (with the exception of weight loss or gain, anorexia, alopecia or fatigue).
o Prior treatment with a kinase inhibitor, biologic therapy, vaccine, or investigational treatment other than cytotoxic therapy or procedure for breast cancer is allowed if administered in the neoadjuvant, adjuvant or metastatic setting = 4 weeks prior to the Baseline Visit.
o Prior treatment with hormonal therapy in the neoadjuvant, adjuvant or metastatic setting is allowed if administered = 2 weeks prior to the Baseline Visit.
o Prior treatment with bevacizumab is allowed if administered in the neoadjuvant or adjuvant setting >4 weeks prior to the Baseline Visit.
5. Prior palliative radiation therapy is allowed if treatment was completed = 2
weeks prior to the Baseline Visit with side effects from radiation resolved.
6. The subject has an Eastern Cooperative Oncology Group (ECOG) performance
status = 1 at the Baseline Visit.
7. The subject has at least one measurable lesion by RECIST (Version 1.1).
o If the selected lesion(s) received prior radiation and/or loco-regional therapy,
there must be evidence of disease progression since the last radiation or
locoregional therapy.
A subject will be excluded from participation if any of the following apply:
1. The subject has hypersensitivity to docetaxel or polysorbate 80.
2. The subject has had a major surgical procedure, substantial open biopsy, or significant traumatic injury within 28 days prior to the Baseline Visit or anticipation of need for major surgical procedure during the course of the study.
3. The subject has neuropathy = Grade 2 at the Baseline Visit.
4. The subject has inadequate marrow, hepatic and/or renal function at the Baseline Visit defined as:
o Serum creatinine = 1.5 x ULN or calculated serum creatinine clearance < 60
mL/min.
o ANC < 1500/mm3.
o Platelets = 100,000/mm3.
o Alanine Transaminase (ALT) or Aspartate Transaminase (AST) >2.5 x ULN, or
>5 x ULN in subjects who have documented liver metastases.
o Bilirubin > ULN.
o Hemoglobin <9 gm/dL
5. Known brain or leptomeningeal metastasis as assessed through medical history review and physical examination.
6. The subject has a known history of positive test for Hepatitis B surface Antigen
(HsbAg) or hepatitis C antibody or history of positive test for Human
Immunodeficiency Virus (HIV).
7. The subject has significant and/or uncontrolled cardiac, renal, hepatic or other
systemic disorders or significant psychological conditions at Baseline Visit that in
the Investigator’s judgment would jeopardize subject enrollment or compliance
with the study procedures.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method